VAL-083: An Important Biological Approach to Fighting Drug-Resistant Tumors

Demonstrating Potency in Clinical Trials

DelMar Pharmaceuticals' lead compound, VAL-083, has been evaluated in more than 40 Phase 1 and Phase 2 clinical trials by the U.S. National Cancer Institute and was found to have anti-cancer activities against various cancers, including brain tumors and ovarian cancers.

Pipeline

Other
Pre-clinical Phase 1 Phase 2 Phase 3 NDA
Single Agent: Recurrent TMZ-resistant (MDACC) MGMT-unmethylated GBM
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NDA Phase not started
Combination with XRT: Newly Diagnosed (Sun Yat-sen University) MGMT-unmethylated GBM
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NDA Phase not started
Ovarian cancer
Pre-clinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
NDA Phase not started
Pediatric Brain Tumor
Pre-clinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
NDA Phase not started

Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is the most common and lethal form of brain cancer. As a unique small molecule therapeutic, VAL-083 can potentially offer a new paradigm in the treatment of GBM.

Glioblastoma Multiforme

Ovarian Cancer

Our research supports VAL-083's potential as a new therapeutic option for platinum-resistant ovarian cancer patients whose treatment is underserved by currently available therapy.

Ovarian Cancer

Pediatric Brain Tumors

Children with high grade glioma have very limited treatment options. VAL-083 has demonstrated promising activities in the treatment of pediatric brain tumors in NCI clinical trials and our recent preclinical studies, supporting future clinical evaluation.

Pediatric Cancer

Our Platform Strategy: Unleashing the Potential of Biology

Our drug development strategy is built on a robust understanding of cancer biology. We use modern scientific approaches to determine where we can solve problems for specific tumor types.

Our team is identifying opportunities where a modernized understanding of the anti-cancer mechanism of VAL-083 suggests that this agent can address an unmet need. By showing that VAL-083 is active where others fail, we can demonstrate that our therapies may have the ability to improve patient survival and quality of life.

Explore Our Scientific Publications & Presentations

Dive deeper into our work by reviewing our robust catalog of scientific publications and presentations.

View Publications and Presentations